Staging of thoracic malignancies is of the utmost importance to the proper treatment of patients with
thoracic malignancies. The 1988 American Joint Committee on Cancer Staging (AJCC) criteria
defined the tumor, node, metastasis (TNM) staging for lung and esophageal carcinoma [1,2]. These
staging criteria are based on survival statistics, which allow the stage groups to be used to predict
outcome after cancer treatment. In addition, the definitive staging of patients with thoracic
malignancies correctly allocates patients to treatment regimens appropriate for their disease stage.
This enables adjuvant and neoadjuvant treatment to be given to patients who will truly derive the
greatest benefit and in whom it will be worthwhile to undertake the possible risks and side effects of
Thoracoscopy is an excellent means for staging intrathoracic malignancies. Thoracoscopy affords an
excellent view of the entire thoracic cavity, including the mediastinum, and thus, is a good tool for
biopsy of mediastinal lymph nodes. Thoracoscopic evaluation of the pleural cavity can clearly show
invasion of the chest wall by intrathoracic malignancies. It also permits evaluation of the entire
parietal pleural surface and the visceral pleural surface of the lung.
The modern lung cancer staging system was described by Naruke and Mountain [3,4]. The clinical
importance of this system is its ability to successfully predict the outcome of patients on the basis of
TNM staging. Most important is the distinction between hilar and mediastinal lymph node
involvement in these patients (Figures 1 and 2). Not only has this staging system proven to be a
useful prognosticator, but treatment strategies based on the presence or absence of mediastinal
lymph node involvement have proven to be important in managing patients with lung cancer .
Although Whittesey  described the usefulness of the CT scan in predicting lymph node invasion in
1988, this noninvasive tool still remains only approximately 85% accurate in predicting malignant
lymph nodes when lymph nodes are > 1.5 cm in size.
Lymph node stage is an important independent prognostic indicator in esophageal carcinoma
(Figures and 4), as noted by Ellis et al . Skinner et al  stressed the importance of node stage
and recommended extended resection for esophageal cancer depending on operative lymph node
Akiyama et al  found that the pattern of lymph node spread in esophageal cancer showed
metastasis to at least one thoracic node station in almost all cases. Metastasis to distant lymph
nodes was not uncommon in their series.
Preoperative staging of thoracic lymph node stations would be likely to reflect the actual lymph
node status, provided that all lymph node stations could be assessed prior to surgery. Preoperative
staging of esophageal cancer may allow us to allocate adjuvant therapy to patients in whom it would
be most beneficial.
The classic approaches to mediastinal lymph node sampling include a variety of invasive techniques.
Mediastinoscopy, described by Harken et al  in 1954 and popularized by Carlens  in
1959, is the standard tool for mediastinal lymph node biopsy. One limitation of this technique is the
difficulty in sampling the aortopulmonary window and left para-aortic lymph nodes. Although
extended transcervical mediastinoscopic biopsy of the aortopulmonary window is possible, it is a
relatively complicated procedure . Also, biopsy of subcranial lymph nodes may be difficult,
especially when nodes are inferior and posterior. Lastly, mediastinoscopy also is not useful for
biopsying masses in the anterior mediastinum, as this region is inaccessible to the mediastinoscope.
The Chamberlain procedure (parasternal anterior mediastinotomy) provides an excellent approach
to lymph node biopsy of the anterior mediastinum . It is particularly useful for biopsy of the
aortopulmonary window and para-aortic lymph nodes on the left but can also access lymph nodes
or mediastinal masses on the right. The mediastinoscope can be inserted into the pleural space at the
same sitting to further stage local disease.
Desauliers et al described a combination of mediastinoscopy, pleuroscopy, and bimanual palpation
to document lymph node involvement in the mediastinum . The disadvantages of the
Chamberlain procedure include the frequent requirement for rib resection, with resultant pain, longer
hospital stay for recuperation, and a more disfiguring cosmetic result, compared with
Although proven in lung cancer, only recently has the importance of mediastinal lymph nodes been
clarified in patients with esophageal cancer. In 1993, the initial results with thoracoscopic staging of
esophageal cancer were reported. Although thoracic nodes were correctly staged in all patients,
celiac nodes were missed in two patients . Since then, routine thoracoscopic and laparoscopic
lymph node staging has been used in patients with esophageal carcinoma with excellent results.
Although as yet, there is no consensus regarding the role of surgical staging in patients with
esophageal cancer, the results of pilot trials in which patients were treated with neoadjuvant therapy
promise an important future role for this new technique in separating advanced esophageal cancer
from local disease.
For patients with lung cancer, thoracoscopy is an excellent tool to augment other noninvasive and
minimally invasive staging procedures. T3 lesions with suspicious direct spread to the chest wall can
be evaluated prior to formal resection. Similarly, in patients who have suspicious T4 lesions with
questionable mediastinal invasion, thoracoscopy can differentiate between abutment of the
mediastinal pleura and mediastinal invasion by tumor. Thus, thoracoscopy can help avoid
unnecessary thoracotomy in high-risk patients in whom one would want to avoid an unnecessary
chest wall incision.
Thoracoscopy is also useful for evaluating primary tumor status in patients with pleural effusions. In
those with suspicious T4 lesions, thoracoscopy may be useful in finding and evaluating malignant
invasion of the pleura or a malignant pleural effusion. It can help determine the presence of pleural
implants or invasion of the pericardium, the vagus, phrenic, or recurrent laryngeal nerves. Again,
thoracoscopy can help avoid an unnecessary thoracotomy for attempted resection in the patient
who is found to have gross disease spread.
Thoracoscopy is a particularly useful tool in evaluating mediastinal lymph nodes. It is used as a
complement to standard cervical mediastinoscopy in evaluation of levels 2 through 11 mediastinal
and hilar lymph nodes. Although mediastinoscopy is excellent for evaluating the upper and lower
paratracheal nodes (American Thoracic Society [ATS] levels 2 through 4), evaluation of the
subcranial nodes (level 7) or aortopulmonary and periaortic lymph nodes (ATS levels 5 and 6) is
either difficult or impossible by standard techniques. We no longer perform the Chamberlain
procedure (parasternal mediastinotomy) to evaluate the aortopulmonary window but instead use
thoracoscopy to assess this area . Thoracoscopy is especially helpful in patients who have
lymph nodes in the aortopulmonary window that are > 1 cm or patients who have left-sided lung
tumors in whom cervical mediastinoscopy does not show positive mediastinal lymph nodes.
Levels 8 and 9 paraesophageal and inferior pulmonary ligament lymph nodes are also considered
N2 mediastinal lymph nodes according to the staging criteria. Despite this, the preoperative staging
of these lymph node stations is almost never accomplished due to the inaccessibility of this region to
cervical mediastinoscopy. Thoracoscopy is a useful tool to biopsy these stations preoperatively
when they are enlarged. Thoracoscopy may help establish whether these stations are actually of the
same prognostic importance as are other mediastinal (N2) lymph nodes.
Some surgeons have even suggested the use of routine thoracoscopic evaluation of the pleural
cavity prior to all thoracotomies for lung cancer resection. The rationale behind this approach is to
rule out previously unsuspected T4 lesions in patients who would otherwise undergo an unnecessary
thoracotomy. At present, other than serving as a very useful training tool, there is no clear advantage
of this technique in routine cases.
Despite aggressive surgical treatment of esophageal cancer, high perioperative morbidity and
mortality are typical. Despite attempts at using combination therapy with chemotherapy, radiation
therapy, and surgical resection in patients with esophageal cancer, 5-year survival rates have been
disappointingly low [17-19]. If a subgroup of patients with a relatively good prognosis could be
selected, survival rates with combination therapy and even standard surgical therapy might be
If it were possible to achieve accurate preoperative staging in esophageal cancer, patients could be
separated prospectively into those likely to have residual local or lymphatic disease and those in
whom complete resection is likely to be attainable. This would enable the physician to allocate
modalities, such as adjuvant chemotherapy and radiation therapy, to the appropriate patient
populations who would derive the greatest benefit, and thus, would limit the morbidity associated
with these treatments.
Although surgery for esophageal carcinoma achieves the best immediate palliation currently
available for dysphagia, many esophageal carcinoma lesions are found at the time of surgery to be
full thickness (T3, T4) or to involve lymph nodes (N1). Mediastinal invasion by an esophageal
carcinoma precludes a safe resection. The pathologic stage differs from the clinical stage in up to
two-thirds of cases showing full-thickness tumors or lymphatic spread. Surgical staging thus may
identify those individuals who are candidates for aggressive palliative or nonsurgical treatment
regimens and avoid unnecessary surgical resections.
Huang and Sun have shown that, among patients with esophageal carcinoma, the 5-year survival
rate in patients without lymph node metastases was 45%, as compared with 13% in those with
lymph node spread. Likewise, when more than five nodes were involved, the survival rate was 0%,
as opposed to 15% when fewer than five nodes were involved . Hagen et al  have recently
claimed an improved survival benefit for patients with complete lymphadenectomy associated with
esophagectomy for distal third and gastroesophageal junction tumors. In 1986 Dagnini et al 
described the routine use of laparoscopy before undertaking esophagectomy for esophageal cancer.
Of 369 patients, intra-abdominal metastases were noted in 14% and celiac lymph node metastases
In 1977 Murray et al  described the use of mediastinoscopy and "mini-laparotomy" in patients
with esophageal cancer. In their series of 30 patients, 5 had positive lymph nodes at
mediastinoscopy and 16 had positive nodes at mini-laparotomy. This finding supports the use of an
operative staging tool to differentiate localized from advanced esophageal cancer.
1. American Joint Committee on Cancer, Task Force on Esophagus, Mountain CF, Chairman:
Carcinoma of the esophagus, in Beahrs OH, Meyers M (eds): Manual for Staging of Cancer, 2nd
Ed, p 61. Philadelphia, JB Lippincott, 1983.
2. American Joint Committee on Cancer, Task Force on Lung, in Beahrs OH, Myers MH, (eds):
Manual for Staging Cancer, pp 115-121. Philadelphia, JB Lippincott, 1988.
3. Naruke T, Goya T, Tsuuchiya R, et al: Prognosis and survival in resected lung cancer based on
the new international staging system. J Thorac Cardiovasc Surg 96:440, 1988.
4. Mountain CF: A new international staging system for lung cancer. Chest 89(suppl):225-233S,
5. Patterson JA, Piazza D, Pearson FG, et al: Significance of metastatic disease in subaortic lymph
nodes. Ann Thorac Surg 43:155-159, 1987.
6. Whittesey D: Prospective computed tomographic scanning in the staging of bronchogenic cancer.
J Thorac Cardiovasc Surg 95:876, 1988.
7. Ellis Jr FH, Watkins Jr. E, Krasna MJ, et al: Staging of carcinoma of the esophagus and cardia:
A comparison of different staging criteria. J Surg Oncol 52:231-235, 1993.
8. Skinner DB, Little A, Ferguson MK, et al: Selection of operation for esophageal cancer based
on staging. Ann Thorac Surg 204:391-401, 1986.
9. Akiyama H, Tsurumaru M, Kawamura T, et al: Principles of surgical treatment for carcinoma of
the esophagus. Ann Surg 194(4):438-446, 1981.
10. Harken DE, Black H, Clauss R, et al: A simple cervicomediastinal exploration for tissue
diagnosis of intrathoracic disease. N Engl J Med 251:1041-1044, 1954.
11. Carlens E: Mediastinoscopy: A method for inspection and tissue biopsy in the superior
mediastinum. Chest 36:343, 1959.
12. Ginsberg RJ, Rice TW, Goldberg M, et al: Extended cervical mediastinoscopy. J Thorac
Cardiovasc Surg 94:673-678, 1987.
13. McNeil TM, Chamberlain JM: Diagnostic anterior mediastinotomy. Ann Thorac Surg 2:532,
14. Desauliers J, Beaulieu M, Defour C, et al: Mediastinopleuroscopy: A new approach to the
diagnosis of intrathoracic disease. Ann Thorac Surg 22:265, 1976.
15. Krasna MJ, McLaughlin JS: Thoracoscopic lymph node staging for esophageal cancer. Ann
Thorac Surg 56:671-674, 1993.
16. Fiocco M, Krasna MJ: Thoracoscopic lymph node dissection in the staging of esophageal
disease. J Laparoendosc Surg 2(2):111-115, 1992.
17. Ellis H, Gibb P, Watkins E: Esophagogastrectomy. Ann Surg 198(4):531-540, 1983.
18. Forastiere AA, Orringer MB, Perez-Tamayo C, et al: Concurrent chemotherapy and radiation
therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin
Oncol 8:119-127, 1990.
19. Ajani JA, Roth JA, Ryan B, et al: Evaluation of pre and postoperative chemotherapy for
resectable adenocarcinoma of the esophagus and gastroesophageal junction. J Clin Oncol
20. Huang G, Sun KL: Prognostic significance of lymph node metastasis in surgical resection of
esophageal carcinoma, in Ferguson MK, Little AG, Skinner, DB (eds): Malignant Diseases, vol 1,
p 213. Mount Kisco, NY, Futura., 1990.
21. Hagen JA, Peters JH, DeMeester TR: Superiority of extended en bloc esophagogastrectomy
for the lower esophagus and cardia. J Thorac Cardiovasc Surg 106:850, 1993.
22. Dagnini G, Caldironi MW, Marin G, et al: Laparoscopy in abdominal staging of esophageal
carcinoma. Gastrointest Endosc 32:400,1986.
23. Murray GF, Wilcox BR, Stared PIK: The assessment of operability of esophageal carcinoma.
Ann Thorac Surg 23:393, 1977.
24. Wolfer RS, Krasna MJ, Hasnain JU, et al: Hemodynamic effects of carbon dioxide insufflation
during thoracoscopy. Ann Thorac Surg 58:404-408,1994.
25. Krasna MJ, Phillips S: Thoracoscopic staging of lung and esophageal cancers, in Toouli J,
Gosset D (eds): Endosurgery, New York, Autchin Livingstone, 1996, in press.
26. Krasna MJ, Flowers JL, Attar S, et al: Combined thoracoscopic and laparoscopic lymph node
staging: the University of Maryland experience, J Thorac and Cardiovasc Surg 1996, in press.
27. Pearson FG, Nelems JM, Henderson RD, et al: The role of mediastinoscopy in the selection of
treatment for bronchial carcinoma with involvement of superior mediastinal lymph nodes. J Thorac
Cardiovasc Surg 64:382-390, 1972.
28. Roviaro G, Varoli F, Rebuffat C, et al: Major pulmonary resections: pneumonectomies and
lobectomies. Ann Thorac Surg 56:779-783, 1993.
29. Maas R, Nicholas V, Grimm H, et al: MRI of esophageal carcinoma with ECG garing at 1.5
Tesla, in Ferguson MN, Little AG, Skinner DB, (eds): Malignant Diseases, vol 1, pp 145-150.
Mount Kisco, NY, Futura, 1990.
30. Rice TW, Boyce GA, Sivall MV: Esophageal ultrasound and the preoperative staging of
carcinoma of the esophagus. J Thorac Cardiovasc Surg 101:536-543, 1991.
31. Krasna MJ, Reed C, Sugarbaker D et al: TSLN staging of esophageal cancer. Ann Thorac
Surg 1995 60:1337-1340.